Table 3 The analyses of factors regarding OS and disease-free survival
Variables | OS | DFS | ||||
|---|---|---|---|---|---|---|
N | Median (Range) | P * | N | Median (Range) | P * | |
Clinico-pathological data | Â | Â | Â | Â | Â | Â |
Pathological types | Â | Â | Â | Â | Â | Â |
   Adenocarcinoma | 25 | 19.0 (1.5-52.5) | 0.860 | 20 | 14.0 (1.0-52.5) | 0.796 |
   Nonadenocarcinoma | 12 | 22.0 (3.0-53.0) |  | 9 | 25.0 (2.0-53.0) |  |
   Serosa invasion |  |  |  |  |  |  |
No (T1/T2) | 8 | 44.0 (2.0-52.5) | 0.024 | 7 | 45.0 (13.0-52.5) | 0.038 |
Yes (T3/T4) | 29 | 13.0 (1.5-53.0) | Â | 22 | 9.3 (1.0-53.0) | Â |
   Lymph node metastasis |  |  |  |  |  |  |
No | 10 | 22.0 (1.5-53.0) | 0.213 | 9 | 38.0 (6.0-52.5) | 0.681 |
Yes | 27 | 12.5 (2.0-33.0) | Â | 20 | 11.3 (1.0-53.0) | Â |
Distant metastasis | Â | Â | Â | Â | Â | Â |
M0 | 29 | 22.0 (1.5-53.0) | 0.021 | Â | Â | Â |
M1 | 8 | 12.5 (2.0-33.0) | Â | Â | Â | Â |
   TNM stage |  |  |  |  |  |  |
Early | 11 | 44.0 (11.0-52.5) | 0.009 | 11 | 46.0 (42.0-52.5) | 0.006 |
Advanced | 26 | 12.0 (1.5-53.0) | Â | Â | 18 | 26.5 (8.0-51.5) |
Immunohistochemistry (IHC) | Â | Â | Â | Â | Â | Â |
   MMP9 |  |  |  |  |  |  |
Positive | 30 | 13.5 (1.5-52.0) | 0.036 | 23 | 9.5 (1.0-51.5) | 0.171 |
Negative | 7 | 44.0 (13.0-53.0) | Â | 6 | 43.5 (25.0-53.0) | Â |
   MMP2 |  |  |  |  |  |  |
Positive | 20 | 14.0 (1.5-53.0) | 0.867 | 13 | 9.0 (1.0-53.0) | 0.395 |
Negative | 17 | 22.0 (7.0-51.5) | Â | 16 | 20.0 (4.0-51.5) | Â |
   Type IV collagen |  |  |  |  |  |  |
Positive | 30 | 25.5 (1.5-53.0) | 0.044 | 25 | 19.0 (1.0-53.0) | 0.646 |
Negative | 7 | 10.0 (2.0-42.0) | Â | 4 | 9.3 (2.0-42.0) | Â |
   Macrophages |  |  |  |  |  |  |
Low density | 16 | 40.5 (1.5-53.0) | 0.056 | 16 | 37.0 (1.0-53.0) | 0.013 |
High density | 21 | 13.0 (2.0-53.0) | Â | 21 | 9.5 (2.0-49.0) | Â |
   MVD |  |  |  |  |  |  |
Low | 19 | 39.0 (11.0-53.0) | 0.001 | 16 | 21 (3.0-53) | 0.209 |
High | 18 | 8.5 (1.5-53.0) | Â | 13 | 6.0 (0.5-49.0) | Â |